Kivizidiale

Timolol and Travoprost, the active ingredients in Kivizidiale, are a beta blocker and a prostaglandin analog presented as eye drops for ocular use. They are used to lower intra‑ocular pressure in patients with primary open‑angle glaucoma or ocular hypertension. GNH USA supplies Kivizidiale as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kivizidiale is indicated for conditions involving elevated intra‑ocular pressure.

Primary open‑angle glaucoma: reduces intra‑ocular pressure to prevent optic nerve damage. Ocular hypertension: lowers intra‑ocular pressure to reduce the risk of progression to glaucoma. Secondary open‑angle glaucoma: assists in controlling pressure when other therapies are insufficient.

Kivizidiale may cause ocular and systemic adverse reactions.

Common Side Effects: - Eye irritation or burning sensation - Blurred vision - Redness of the eye - Itching or mild discomfort - Dry eye sensation - Foreign body feeling in the eye

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angioedema, anaphylaxis) - Worsening of glaucoma or sudden increase in pressure - Chest pain or bradycardia due to systemic beta‑blockade - Bronchospasm or severe asthma exacerbation - Ocular inflammation or uveitis - Systemic hypotension or heart block

Before prescribing Kivizidiale, clinicians should evaluate patient‑specific risk factors.

Cardiovascular assessment: monitor heart rate and blood pressure in patients with cardiac disease. Respiratory status: avoid in patients with severe asthma or COPD. Concurrent beta‑blocker therapy: assess for additive systemic effects. Pregnancy and lactation: use only if the potential benefit outweighs risk. Contact lens wear: advise removal before instillation and avoid wearing lenses for several hours after dosing. Store at room temperature: keep bottle tightly closed, protect from light and moisture.

Kivizidiale can interact with several systemic and ocular agents.

Major Interactions (Avoid): - Systemic beta‑blockers: may cause additive bradycardia or hypotension. - Asthma or COPD medications (beta‑agonists): risk of reduced bronchodilator efficacy.

Moderate Interactions (Monitor Closely): - Other prostaglandin analog eye drops: increased risk of ocular side effects. - Topical anesthetics: may enhance corneal toxicity. - Carbonic anhydrase inhibitors: additive intra‑ocular pressure lowering effect. - Anticholinergic eye drops: possible alteration of pupil dynamics.